28  Dealing with retrieval bias for an evidence-informed individual patient data network meta-analysis. (18th July 2022)

• Record Type: Journal Article
• Authors: Veroniki, Areti Angeliki; Ashoor, Huda; Rios, Patricia; Seitidis, George; Mavridis, Dimitris; Straus, Sharon; Tricco, Andrea
• Is Part Of: BMJ evidence-based medicine. Volume 27(2022)Supplement 2
• Page Start: A1
• Page End: A1
• Publication Date: 2022-07-18
• Subjects: Evidence-based medicine -- Periodicals; 616.005
• DOI: 10.1136/ebm-2022-EBMLive.1
• Languages: English
• ISSNs: 2515-446X

Abstract

Abstract : Objectives: The synthesis of individual patient data (IPD) from randomised clinical trials (RCTs) can strengthen evidence used for decision-making. Network meta-analyses (NMA) modelling IPD usually include non-sponsored or publicly sponsored RCTs. Evidence suggests that IPD sharing may depend on study characteristics, such as funding type, RCT size, RCT risk of bias, and treatment effect. However, retrieval bias in IPD-NMA of sponsored RCTs has not been assessed before. The objective of this study is to explore retrieval bias in IPD-NMAs of sponsored RCTs and address challenges and barriers. Method: We contacted authors and sponsors of RCTs eligible for 2 IPD-NMAs to obtain IPD. If a study had multiple sponsors, we contacted all of them. To facilitate IPD retrieval, we contacted data sharing platforms. All IPD were checked for consistency with results from published RCTs. We explored whether IPD studies suggested different findings with those of studies not sharing IPD and outlined the IPD availability from sponsors. We noted all barriers and resource requirements associated with the IPD acquisition during the author and sponsor contact processes. Results: We included 137 RCTs and received IPD for 29 (21%) RCTs (1058 total waiting days). None of the authors shared their IPD. Instead, 17 sponsors for 107 studies were contacted and 7 sponsors shared their data through their platforms. The 7 sponsors held data for 94 RCTs and we obtained data from 31% (29/94) of these RCTs. Of the 29 RCTs, we were able to include 23 RCTs in our NMA due to incompleteness of provided data. For example, a study included only IPD for the placebo arm and thus was excluded from the NMA. A big challenge in the IPD was the high dropout rate (up to 72%) from the RCTs, for which many original authors applied inappropriate imputation methods. Our findings differed from published RCT results. We encountered outcome reporting bias; specifically, some outcomes were missing from the publications but were available as IPD. Conclusions: Retrieval bias can severely impact NMA findings and decision-making. Our study highlighted challenges encountered during an IPD-NMA of sponsored RCTs.